NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme essential for cellular energy, DNA repair, and healthy aging
2023 | Evidence expands the playing field The new year kicked off with a whirlwind of interest, both scientific and financial, largely centred around a growing rivalry between Novo Nordisk and Eli Lilly
Looking to transform your health with medical weight loss
As of August 2025, more than 1,800 lawsuits have been consolidated into federal multidistrict litigation (MDL), and legal experts expect that number to rise sharply
In addition, those using a GLP-1 RA had a 16% lower MACE risk than those who did not use a GLP-1
This move marks a major development in the weight-loss drug market, which has been dominated by Novo Nordisk GLP-1 portfolio (Saxenda, Wegovy, Ozempic)